The Davio 2 Trial for Neovascular AMD

Update: 2024-05-31

Description

We review the 6 month results of the Davio 2 trial of the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.

Comments

In Channel

Untitled EpisodeArtificial Intelligence in the Management of Macular Disease

2025-12-0324:12

Stem Cell Therapy for Geographic Atrophy

2025-11-1926:15

Intravitreal Gene Therapy for Neovascular AMD

2025-11-1319:49

The TRUCKEE Study of Faricimab for Neovascular AMD

2025-11-0515:07

The VERONA Trial of a TKI for the Treatment of DME

2025-10-2909:46

Photobiomodulation for the Treatment of Dry AMD

2025-10-2413:41

8 mg Aflibercept in Diabetic Macular Edema

2025-10-0811:18

Subretinal Gene Therapy for Neovascular AMD

2025-10-0316:26

Does Pegcetacoplan Treatment Affect Dry Macular Degeneration?

2025-09-2509:01

Rapid Fluid Resolution with Aflibercept 8mg may be Associated with Extended Dosing Intervals in nAMD

2025-09-0820:58

The Good Days Dilemma - Support for Patient Co-Payments in Retinal Pharmacotherapy

2025-08-2812:43

Immediate vs Delayed Treatment of GA with Pegcetacoplan

2025-08-1917:33

Eyes with both Geographic Atrophy and Neovascular AMD: An IRIS Study

2024-07-1212:07

The Davio 2 Trial for Neovascular AMD

2024-05-3113:47

The GALE Extension Study

2024-05-1715:06

AXPAXLI for Diabetic Retinopathy

2024-05-0904:44

NSAIDS in the treatment of Central Serous Chorioretinopathy

2024-04-1814:22

EY-103 a novel Wnt Pathway Agonist for Treatment of DME and neovascular AMD

2024-04-0421:41

Intravitreal Gene Therapy for neovascular AMD with 4D-150

2024-03-2813:44

KSI 501 Bispecific Anti-VEGF Biopolymer Treatment of DME

2024-03-2107:38

00:00

The Davio 2 Trial for Neovascular AMD

#box-pro-ellipsis-176535341916454{-webkit-line-clamp:2;}The Davio 2 Trial for Neovascular AMD

The Davio 2 Trial for Neovascular AMD

Retina Synthesis

The Davio 2 Trial for Neovascular AMD